Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May;104(5):e211-e214.
doi: 10.3324/haematol.2018.205229. Epub 2018 Nov 15.

Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis

Simon Rule  1 , Martin Dreyling  2 , Andre Goy  3 , Georg Hess  4 , Rebecca Auer  5 , Brad Kahl  6 , José-Ángel Hernández-Rivas  7 , Keqin Qi  8 , Sanjay Deshpande  8 , Lori Parisi  8 , Michael Wang  9
Affiliations

Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis

Simon Rule et al. Haematologica. 2019 May.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan-Meier curves of progression-free survival (PFS) and overall survival (OS) in pooled population including the CAN3001 study. (A) Patients with 1 prior line of therapy before ibrutinib treatment had longer median PFS than those with >1 prior line: 25.4 (95%CI: 17.5-57.5) vs. 10.3 (95%CI: 8.1-12.5) months. (B) Patients with 1 prior line of therapy before ibrutinib treatment had longer median overall survival than those with >1 prior line: NR (95%CI: 36.0-NE) versus 22.5 (95%CI: 16.2-26.7) months. CI: confidence interval; mo: months; NE: not estimable; NR: not reached.
Figure 2.
Figure 2.
Incidence of treatment-emergent adverse events (TEAEs) over time. (A) Grade ≥3 TEAEs generally decreased over time with lower rates associated with ibrutinib use in second versus later lines. (B) Any-grade serious TEAEs generally decreased over time with lower rates associated with ibrutinib use in second versus later lines. (C) Incidence of grade ≥3 AF and bleeding was highest in year 1 and decreased thereafter. Overall population is the full ibrutinib cohort enrolled in the original three studies (N=370), including those who continued on to the CAN3001 study. Number of patients with adverse events shown on bars. Recurrent events per patient were counted only once per year. If recurrent events occurred in a single patient in separate years, these were counted separately in each year (once only per year). N: number; AF: atrial fibrillation; Yr: year.
See this image and copyright information in PMC

References

    1. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009; 27(4):512–518. - PubMed
    1. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013; 369(6):507–516. - PMC - PubMed
    1. Dreyling M, Campo E, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4):iv62–iv71. - PubMed
    1. Rule S, Dreyling M, Goy A, et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. Br J Haematol. 2017;179(3):430–438. - PMC - PubMed
    1. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586. - PubMed

Publication types

MeSH terms